Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 14/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 14/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117496 | 0.94 | GAA (0.51) | PRMT5WDR77GAAMAPTCYP3A4 | |
| SCHEMBL23909056 | 0.82 | SMN1; SMN2 (0.69) | PRMT5WDR77GAAMAPTENPP1 | |
| SCHEMBL23914748 | 0.82 | SMN1; SMN2 (0.69) | PRMT5WDR77GAAMAPT | |
| SCHEMBL4131883 | 0.81 | GAA (0.50) | PRMT5WDR77GAAMAPTCYP3A4 | |
| SCHEMBL4837939 | 0.80 | MAPT (0.47) | PRMT5WDR77GAAMAPTCYP3A4 | |
| SCHEMBL10271452 | 0.80 | ITK (0.45) | MAPTCYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL24076247 | 0.80 | PRMT5 (0.49) | PRMT5WDR77AR | |
| SCHEMBL2305371 | 0.80 | DYRK1A (0.59) | PRMT5WDR77GAAMAPTENPP1 | |
| SCHEMBL17232485 | 0.80 | KDM4E (0.50) | MAPTTSHRDYRK1A | |
| SCHEMBL4833670 | 0.79 | PARP1 (0.66) | GAAMAPTCYP3A4CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| EP-1097142-B1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-10-13 | — | — | EP | disclosed |
| US-6492360-B1 | Phthalazine derivatives phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2002-12-10 | — | — | US | disclosed |
| US-6329370-B1 | CARDIOVASCULAR DISORDERS AND TUMOR NECROSIS FACTOR (HEREINAFTER TNF.SUB..ALPHA.), A CYTOKINE WITH PRO-INFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2001-12-11 | — | — | US | disclosed |
| EP-1097142-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000005218-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | PRMT5 3337/4885WDR77 1820/4885GAA 4369/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | PRMT5 3882/4885WDR77 3615/4885GAA 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.